Jenburkt Pharmaceuticals Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹675
- Today's High:
- ₹710.3
- Open Price:
- ₹710.3
- 52W Low:
- ₹515.5189
- 52W High:
- ₹785.0292
- Prev. Close:
- ₹701.4
- Volume:
- 2761
Company Statistics
- Market Cap.:
- ₹1.66 billion
- Book Value:
- 191.469
- Revenue TTM:
- ₹1.12 billion
- Operating Margin TTM:
- 16.55%
- Gross Profit TTM:
- ₹851.36 million
- Profit Margin:
- 14.26%
- Return on Assets TTM:
- 10.88%
- Return on Equity TTM:
- 19.28%
Company Profile
Jenburkt Pharmaceuticals Limited had its IPO on under the ticker symbol 524731.
The company operates in the Other sector and Other industry. Jenburkt Pharmaceuticals Limited has a staff strength of 1,006 employees.
Stock update
Shares of Jenburkt Pharmaceuticals Limited opened at ₹710.3 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹675 - ₹710.3, and closed at ₹684.45.
This is a -2.42% slip from the previous day's closing price.
A total volume of 2,761 shares were traded at the close of the day’s session.
In the last one week, shares of Jenburkt Pharmaceuticals Limited have slipped by -2.57%.
Jenburkt Pharmaceuticals Limited's Key Ratios
Jenburkt Pharmaceuticals Limited has a market cap of ₹1.66 billion, indicating a price to book ratio of 2.0786 and a price to sales ratio of 1.6333.
In the last 12-months Jenburkt Pharmaceuticals Limited’s revenue was ₹1.12 billion with a gross profit of ₹851.36 million and an EBITDA of ₹196.95 million. The EBITDA ratio measures Jenburkt Pharmaceuticals Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Jenburkt Pharmaceuticals Limited’s operating margin was 16.55% while its return on assets stood at 10.88% with a return of equity of 19.28%.
In Q3, Jenburkt Pharmaceuticals Limited’s quarterly earnings growth was a positive 2.1% while revenue growth was a negative 10.8%.
Jenburkt Pharmaceuticals Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 11.4584
- PEG
Its diluted EPS in the last 12-months stands at ₹34.732 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Jenburkt Pharmaceuticals Limited’s profitability.
Jenburkt Pharmaceuticals Limited stock is trading at a EV to sales ratio of 1.0442 and a EV to EBITDA ratio of 4.7021. Its price to sales ratio in the trailing 12-months stood at 1.6333.
Jenburkt Pharmaceuticals Limited stock pays annual dividends of ₹18.3 per share, indicating a yield of 4.54% and a payout ratio of 32.84%.
Balance sheet and cash flow metrics
- Total Assets
- ₹1.42 billion
- Total Liabilities
- ₹157.62 million
- Operating Cash Flow
- ₹26.18 million
- Capital Expenditure
- ₹21.05 million
- Dividend Payout Ratio
- 32.84%
Jenburkt Pharmaceuticals Limited ended 2024 with ₹1.42 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹1.42 billion while shareholder equity stood at ₹1.22 billion.
Jenburkt Pharmaceuticals Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹157.62 million in other current liabilities, 44133000.00 in common stock, ₹1.18 billion in retained earnings and ₹0.00 in goodwill. Its cash balance stood at ₹0 and cash and short-term investments were ₹545.83 million. The company’s total short-term debt was ₹24,410,000 while long-term debt stood at ₹0.
Jenburkt Pharmaceuticals Limited’s total current assets stands at ₹810.91 million while long-term investments were ₹0 and short-term investments were ₹7.73 million. Its net receivables were ₹169.62 million compared to accounts payable of ₹0 and inventory worth ₹83.38 million.
In 2024, Jenburkt Pharmaceuticals Limited's operating cash flow was ₹26.18 million while its capital expenditure stood at ₹21.05 million.
Comparatively, Jenburkt Pharmaceuticals Limited paid ₹0.33 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹684.45
- 52-Week High
- ₹785.0292
- 52-Week Low
- ₹515.5189
- Analyst Target Price
- ₹
Jenburkt Pharmaceuticals Limited stock is currently trading at ₹684.45 per share. It touched a 52-week high of ₹785.0292 and a 52-week low of ₹785.0292. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹726.44 and 200-day moving average was ₹677.04 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 5319.5% of the company’s stock are held by insiders while 222.1% are held by institutions.
Frequently Asked Questions About Jenburkt Pharmaceuticals Limited
Similar Industry Stocks (Other)
Most Active
Top Gainers
Top Losers
About
Jenburkt Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical formulations primarily in India. It offers products in various therapeutic areas, such as pain management, neuropathic pain, anthelmintics, analgesics and antipyretics, anti-arthritic, anti-diabetic, anti-infective, anti-fungal, anti-malarial, anti-ulcerant/antacid, aphrodisiac, cough and cold, and muscle relaxants, as well as nutraceutical and consumer products. The company provides its products through stockists and super stockists to doctors, chemists, large government and semi-government institutions, missionary hospitals, public sector enterprises, etc. It also exports its products to approximately 13 countries. The company was founded in 1985 and is based in Mumbai, India.